Strata Critical Medical, Inc.
Business
Strata Critical Medical, Inc. provides air transportation and logistics services that arrange passenger flights and transport of human organs for transplant, operating an asset-light platform that coordinates third-party aircraft and select owned aircraft. It offers short-distance helicopter and amphibious seaplane flights, non-medical jet charters and ground connections, MediMobility organ transport, donor logistics coordination, and Trinity Organ Placement Services (TOPS). The company operates through Passenger and Medical segments with product lines for Short Distance, Jet and Other, and organ transport/TOPS. Services are delivered primarily in the Northeast United States and Southern Europe via exclusive passenger terminals, a customer-facing app and web platform, and a network of third-party operators.
Summary from filing dated 2025-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Revenue | 197 | 147 | 225 | 146 | 51 | |
| Cost of revenue | 156 | 117 | 183 | 124 | 40 | |
| Gross Profit | 41 | 30 | — | — | — | |
| Selling, general and administrative | 61 | 51 | — | — | — | |
| Amortization of intangible assets | 3 | 1 | — | — | — | |
| Total operating expenses | 63 | 52 | — | — | — | |
| Operating loss from continuing operations | −22 | −23 | −68 | −54 | −24 | |
| Interest income | 4 | 7 | 8 | — | — | |
| Change in fair value of warrant liabilities | 4 | −850,000 | 2 | 24 | −18 | |
| Change in fair value of assets and other liabilities | −1 | 0 | — | — | — | |
| Realized loss from sales of short-term investments | −5 | 0 | 8,000 | −2 | 0 | |
| Total other non-operating income | 2 | 6 | 11 | 25 | −20 | |
| Loss from continuing operations before income taxes | −20 | −16 | −58 | −28 | −44 | |
| Income tax expense from continuing operations | 0 | 0 | −1 | −772,000 | −4 | |
| Net loss from continuing operations | −20 | −16 | — | — | — | |
| Net income (loss) from discontinued operations | 61 | −11 | — | — | — | |
| Net income (loss) | 41 | −27 | −56 | −27 | −40 | |
| Continuing operations, basic (in dollars per share) | −0.24 | −0.21 | — | — | — | |
| Continuing operations , diluted (in dollars per share) | −0.24 | −0.21 | — | — | — | |
| Discontinued operations, basic (in dollars per share) | 0.75 | −0.14 | — | — | — | |
| Discontinued operations, diluted (in dollars per share) | 0.75 | −0.14 | — | — | — | |
| Total basic earnings (loss) per share (in dollars per share) | 0.5 | −0.35 | −0.76 | −0.38 | −0.93 | |
| Total diluted earnings (loss) per share (in dollars per share) | 0.5 | −0.35 | −0.76 | −0.38 | −0.93 | |
| Basic (in shares) | 82 | 77 | 74 | 71 | 43 | |
| Diluted (in shares) | 82 | 77 | 74 | 71 | 43 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 31 | 16 | — | — | — | |
| Restricted cash | 264,000 | 263,000 | 1 | 3 | 630,000 | |
| Accounts receivable, net of allowance of $1,066 and $ at December 31, 2025 and December 31, 2024, respectively | 40 | 20 | 21 | 11 | 6 | |
| Short-term investments | 30 | 109 | 138 | 151 | 279 | |
| Prepaid expenses and other current assets | 25 | 5 | 18 | 12 | 7 | |
| Current assets of discontinued operations | 0 | 11 | — | — | — | |
| Total current assets | 126 | 161 | 206 | 218 | 295 | |
| Property and equipment, net | 36 | 28 | 3 | 2 | 2 | |
| Intangible assets, net | 48 | 8 | 21 | 46 | 24 | |
| Goodwill | 88 | 16 | 13 | 39 | 13 | |
| Operating right-of-use asset | 3 | 3 | 23 | 18 | 713,000 | |
| Other non-current assets | 24 | 118,000 | 1 | 1 | 232,000 | |
| Non current assets of discontinued operations | 0 | 41 | — | — | — | |
| Total assets | 325 | 257 | 295 | 325 | 336 | |
| Accounts payable and accrued expenses | 19 | 9 | 24 | 17 | 6 | |
| Operating lease liability, current | 652,000 | 682,000 | 5 | 3 | 438,000 | |
| Current liabilities of discontinued operations | 0 | 13 | — | — | — | |
| Total current liabilities | 20 | 23 | 35 | 27 | 13 | |
| Warrant liability | 2 | 6 | 5 | 7 | 31 | |
| Operating lease liability, long-term | 3 | 2 | 20 | 15 | 278,000 | |
| Deferred tax liability | 348,000 | 0 | 451,000 | 2 | 144,000 | |
| Other non-current liabilities | 22 | 0 | — | — | — | |
| Non-current liabilities of discontinued operations | 0 | 4 | — | — | — | |
| Total liabilities | 46 | 35 | 61 | 51 | 45 | |
| Commitments and Contingencies (Note 14) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,702,183 and 79,419,028 shares issued at December 31, 2025 and December 31, 2024, respectively | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | |
| Additional paid in capital | 425 | 407 | 390 | 376 | 369 | |
| Accumulated other comprehensive income | 0 | 2 | 4 | 2 | −898,000 | |
| Accumulated deficit | −146 | −187 | −160 | −104 | −76 | |
| Total stockholders' equity | 279 | 222 | 234 | 274 | 291 | |
| Total liabilities and stockholders' equity | 325 | 257 | 295 | 325 | 336 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Gain on sale of business | −57 | 0 | — | — | — | |
| Depreciation and amortization | 8 | 6 | 7 | 6 | 596,000 | |
| Stock-based compensation | 18 | 20 | 13 | 8 | 10 | |
| Excess of lease liability over operating right-of-use assets | 0 | −123,000 | 0 | — | — | |
| Transaction costs paid related to sale of business | −7 | 0 | — | — | — | |
| Gain on lease modification | 0 | −622,000 | 0 | — | — | |
| Acquisition consideration allocated to seller transaction expenses | −44 | 0 | — | — | — | |
| Impairment of intangible assets | 0 | 6 | — | — | — | |
| Impairment of property and equipment | 2 | 0 | — | — | — | |
| Realized foreign exchange gain | −798,000 | 0 | — | — | — | |
| Accretion of interest income on held-to-maturity securities | −2 | −4 | −7 | −1 | 0 | |
| Deferred tax expense (benefit) | 432,000 | −255,000 | −1 | −772,000 | −4 | |
| Other | 471,000 | 323,000 | 46,000 | — | — | |
| Prepaid expenses and other current assets | −2 | 6 | −6 | −5 | −4 | |
| Accounts receivable | −12 | −998,000 | −10 | −5 | −414,000 | |
| Other non-current assets | 666,000 | −70,000 | 4,000 | −663,000 | −119,000 | |
| Operating right-of-use assets/lease liabilities | −88,000 | 164,000 | 379,000 | 611,000 | 3,000 | |
| Accounts payable and accrued expenses | 2 | −8 | 9 | 10 | 2 | |
| Deferred revenue | 2 | −119,000 | 117,000 | 737,000 | 681,000 | |
| Net cash used in operating activities | −49 | −3 | −32 | −37 | −16 | |
| Acquisitions, net of cash acquired | −67 | −2 | 0 | −48 | −23 | |
| Cash transfer from sale of business | −3 | 0 | — | — | — | |
| Capitalized software development costs | −1 | −2 | 0 | 0 | 0 | |
| Purchase of property and equipment, net of proceeds from disposal | −10 | −31 | −2 | −730,000 | −297,000 | |
| Purchase of held-to-maturity investments | −146 | −143 | −266 | −227 | 0 | |
| Proceeds from maturities of held-to-maturity investments | 226 | 177 | 265 | 98 | 0 | |
| Proceeds from sale of short-term investments | 70 | 0 | 21 | 258 | 11 | |
| Net cash provided by / (used in) investing activities (includes discontinued operations; see Note 5) | 70 | −1 | 17 | 79 | −321 | |
| Proceeds from the exercise of common stock options | 193,000 | 168,000 | 70,000 | 87,000 | 144,000 | |
| Taxes paid related to net share settlement of equity awards | −9 | −6 | −146,000 | −1 | −52,000 | |
| Repurchase and retirement of common stock | 0 | −244,000 | 0 | — | — | |
| Net cash used in financing activities | −9 | −6 | −76,000 | −1 | 332 | |
| Effect of foreign exchange rate changes on cash balances | −339,000 | −80,000 | −66,000 | 72,000 | 0 | |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 12 | −9 | −15 | 41 | −5 | |
| Income Taxes paid | 87,000 | 0 | 16,000 | 0 | 0 | |
| Common stock received for sale of business | 75 | 0 | — | — | — | |
| Contingent consideration and indemnity holdback receivable from sale of business in prepaids and other current assets and other non-current assets, respectively | 36 | 0 | — | — | — | |
| New leases under ASC 842 entered into during the period | 2 | 8 | 10 | 6 | 13,000 | |
| Contingent consideration in accounts payable and accrued expenses and other non-current liabilities | 9 | 0 | — | — | — | |
| Common stock issued for acquisition | 8 | 0 | — | — | — | |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 128,000 | 375,000 | 0 | — | — | |
| "Modification of existing right-of-use assets (""ROU"") and lease liability" | 0 | 13 | 0 | — | — | |
| Derecognition of ROU assets and lease liability | 0 | −6 | 0 | — | — | |
| Common stock issued for settlement of earn-out previously in accounts payable and accrued expenses | 0 | 3 | 2 | — | — |